Anzeige
Mehr »
Login
Mittwoch, 04.12.2024 Börsentäglich über 12.000 News von 680 internationalen Medien
Analysten eilen, um Kursziele zu verdreifachen nach ATHAs neuester Entdeckung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Edison Investment Research-Archiv vom 10.07.2024

ZeitNachrichten
Sprache: Alle DE EN
LeserMedien
10.07.Kolibri Global Energy - New approach to drilling; potential share buyback313Kolibri Global Energy (KEI) has provided an update on operations and revised guidance. It now guides to FY24 revenue of US$57-62m and EBITDA of US$43-48m on average production of 3,200-3,700boepd. KEI...
► Artikel lesen
10.07.Revolution Beauty - Returning to profitability393Revolution Beauty's (REVB's) FY24 results demonstrated the new management team's progress on its updated strategy. Although revenue growth was relatively muted at c 2%, the streamlining of the brand...
► Artikel lesen
10.07.Supermarket Income REIT - The next stage of growth822Supermarket Income REIT's (SUPR's) high-quality, omnichannel-focused portfolio is very well positioned to benefit from strong growth trends in the grocery sector. Moreover, with supermarket property...
► Artikel lesen
10.07.AFT Pharmaceuticals - Continued execution of footprint expansion247AFT Pharmaceuticals continues to make inroads in expanding its strategic market footprint. Most recently, it announced the entry into China with the distribution of Crystaderm (approved by Chinese regulators...
► Artikel lesen
10.07.Solid State - Record FY24; medium-term targets retained245Solid State is developing from a component manufacturer into a value-added electronics partner offering engineered solutions. Management expects this to drive additional growth and margin expansion...
► Artikel lesen
10.07.Immix Biopharma - US CAR-T trial commences patient dosing251Immix has announced that the first patient has been dosed in its Phase Ib NEXICART-2 trial of lead CAR-T asset NXC-201, which took place at lead study site, the Memorial Sloan Kettering Cancer Center....
► Artikel lesen